质子束疗法治疗胃癌肝转移复发的疗效。

The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients.

机构信息

Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima City, Fukushima, Japan.

Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, Fukushima, Japan.

出版信息

Jpn J Clin Oncol. 2020 Aug 4;50(8):903-908. doi: 10.1093/jjco/hyaa052.

DOI:10.1093/jjco/hyaa052

PMID:32363379

Abstract

OBJECTIVE

The purpose of this cross-sectional study was to evaluate the efficacy and safety of proton beam therapy for liver metastatic recurrence in gastric cancer patients.

METHODS

Consecutive patients who underwent proton beam therapy from 2010 to 2015 were isolated from our institutional database. Patients with extrahepatic metastatic lesions were excluded. Seven patients were enrolled. The median diameter of target lesions was 31 mm (13-68 mm). The most frequent dosage was 72.6 Gy equivalent in 22 fractions. The effectiveness was assessed based on the local control, overall survival and progression-free survival rates. The local control, overall survival and progression-free survival rates were calculated using the Kaplan-Meier method. Adverse events were described according to the patients' medical records.

RESULTS

The median follow-up period was 41.7 months (20.7-66.3 months). The 3-year local control, overall survival and progression-free survival rates were 85.7, 68.6 and 43%, respectively. All patients completed proton beam therapy without interruption. No grade ≥3 adverse events were observed.

CONCLUSIONS

Proton beam therapy might be a treatment option for patients with liver metastasis of gastric cancer.

摘要

目的

本研究旨在评估质子束疗法治疗胃癌肝转移复发的疗效和安全性。

方法

我们从医院的资料库中选取了 2010 年至 2015 年期间接受质子束治疗的连续患者，并排除了肝外转移病灶的患者。共纳入 7 名患者。靶病灶的中位直径为 31mm（13-68mm）。最常见的剂量为 72.6Gy 等效剂量，共 22 次分割。根据局部控制率、总生存率和无进展生存率来评估疗效。采用 Kaplan-Meier 法计算局部控制率、总生存率和无进展生存率。根据患者的病历描述不良反应事件。